International experience by using of the SJMB protocols in treatment of children with medulloblastoma in the age group over 3 years (literature review)

Cover Page

Cite item

Full Text

Abstract

During the last 30 years, unique international experience has been accumulated in the treatment of children with medulloblastoma, especially in the age group over 3 years. Evolutionary representations about one of the most well – known international protocols – SJMB (in versions since 1996 – SJMB96, since 2003 – SJMB03, since 2012 – SJMB12) are shown in this article. Innovative criteria for stratifying patients into risk groups were established according to clinical, therapeutic, morphological and molecular-biological prognostic factors. Despite the accumulated experience, it is necessary to continue studying the relationship between age groups and the molecular biology of tumor cells for the purpose of subsequent optimization of the treatment program.

About the authors

Andrey S. Levashov

Blokhin National Medical Research Center of Oncology

Author for correspondence.
Email: andreyslevashov@mail.ru
ORCID iD: 0000-0001-5081-3964

cand. sci. (med.)

Russian Federation, Moscow

Svetlana R. Zagidullina

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-6606-3106

pediatric oncologist

Russian Federation, Moscow

Timur T. Valiev

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-1469-2365

d. sci. (med.)

Russian Federation, Moscow

Anna M. Stroganova

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-7297-5240

cand. sci. (med.)

Russian Federation, Moscow

Dmitry A. Khochenkov

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-5694-3492

cand. sci. (biol.)

Russian Federation, Moscow

Vasiliy A. Grigorenko

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-2391-4142

radiologist

Russian Federation, Moscow

Elena V. Mikhaylova

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-7630-7496

cand. sci. (med.)

Russian Federation, Moscow

Elizaveta V. Tyurina

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-4019-5247

pediatric oncologist

Russian Federation, Moscow

Marina V. Ryzhova

Burdenko National Medical Research Center of Neurosurgery

Email: editor@omnidoctor.ru
ORCID iD: 0000-0001-7206-6365

d. sci. (med.)

Russian Federation, Moscow

Serhii K. Horielyshev

Burdenko National Medical Research Center of Neurosurgery

Email: editor@omnidoctor.ru
ORCID iD: 0000-0003-1318-7823

d. sci. (med.)

Russian Federation, Moscow

Shavkat U. Kadyrov

Burdenko National Medical Research Center of Neurosurgery

Email: editor@omnidoctor.ru

cand. sci. (med.)

Russian Federation, Moscow

Vladimir G. Polyakov

Blokhin National Medical Research Center of Oncology

Email: editor@omnidoctor.ru
ORCID iD: 0000-0002-8096-0874

d. sci. (med.), prof., acad. RAS

Russian Federation, Moscow

References

  1. McNeill KA. Epidemiology of brain tumors. Neurol Clin. 2016;34(4):981-98. doi: 10.1016/j.ncl.2016.06.014
  2. Ostrom QT, Gittleman H, Xu J, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol. 2016;18(Suppl. 5):v1-v75. doi: 10.1093/neuonc/now207
  3. Ostrom QT, Gittleman H, Truitt G, et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(Suppl. 4):iv1-iv86. doi: 10.1093/neuonc/noy131
  4. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of tumors of the central nervous system: A summary. Acta Neuropathol. 2016;131(6):803-20. doi: 10.1007/s00401-016-1545-1
  5. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: A summary. Neuro Oncol. 2021;23(8):1231-51. doi: 10.1093/neuonc/noab106
  6. Packer RJ, Gajjar A, Vezina G, et al. Phase III Study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24(25):4202-8. doi: 10.1200/JCO.2006.06.4980
  7. Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): Long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7(10):813-20. doi: 10.1016/S1470- 2045(06)70867-1
  8. Clifford SC, Lannering B, Schwalbe EC, et al. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP PNET4 clinical trial. Oncotarget. 2015;6(36):38827-39. doi: 10.18632/oncotarget.5149
  9. Kennedy C, Bull K, Chevignard M, et al. Quality of survival and growth in children and young adults in the PNET4 European controlled trial of hyperfractionated versus conventional radiation therapy for standard-risk medulloblastoma. Int J Radiat Oncol Biol Phys. 2014;88(2):292-300. doi: 10.1016/j.ijrobp.2013.09.046
  10. Lannering B, Rutkowski S, Doz F, et al. Hyperfractionated versus conventional radiotherapy followed by chemotherapy in standard-risk medulloblastoma: results from the randomized multicenter HIT-SIOP PNET 4 Trial. J Clin Oncol. 2012;30(26):3187-93. doi: 10.1200/JCO.2011.39.8719
  11. Minturn JE, Mochizuki AY, Partap S, et al. A pilot study of low-dose craniospinal irradiation in patients with newly diagnosed average-risk medulloblastoma. Front Oncol. 2021;11:744739. doi: 10.3389/fonc.2021.744739
  12. Gajjar A, Robinson GW, Smith KS, et al. Outcomes by clinical and molecular features in children with medulloblastoma treated with risk – adapted therapy: Results of in International phase III trial (SJMB03). J Clin Oncol. 2021;39(7):822-35. doi: 10.1200/JCO.20.01372
  13. Kumar R, Smith KS, Deng M, et al. Clinical outcomes and patient-matched molecular composition of relapsed medulloblastoma. J Clin Oncol. 2021;39(7):807-21. doi: 10.1200/JCO.20.01359
  14. Michalski JM, Janss AJ, Vezina LG, et al. Children’s Oncology Group phase III trial of reduced-dose and reduced-volume radiotherapy with chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2021;39(24):2685-97. doi: 10.1200/JCO.20.02730
  15. Michalski JM, Janss AJ, Vezina LG, et al. Results of COG ACNS0331: A phase III trial of Involved-Field Radiotherapy (IFRT) and Low Dose Craniospinal Irradiation (LD-CSI) with chemotherapy in average-risk medulloblastoma: A report from the Children’s Oncology Group. Int J Rad Oncol. 2016;96(5):937-8. doi: 10.1016/j.ijrobp.2016.09.046
  16. Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: A pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013;31(23):2936-41. doi: 10.1200/JCO.2012.43.9984
  17. Stewart CF, Iacono LC, Chintagumpala M, et al. Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol. 2004;22(16):3357-65. doi: 10.1200/JCO.2004.10.103
  18. von Bueren AO, Kortmann RD, von Hoff K, et al. Treatment of children and adolescents with metastatic medulloblastoma and prognostic relevance of clinical and biologic parameters. J Clin Oncol. 2016;34(34):4151-60. doi: 10.1200/JCO.2016.67.2428
  19. Dufour C, Foulon S, Geoffray A, et al. Prognostic relevance of clinical and molecular risk factors in children with high risk medulloblastoma treated in the French prospective trial PNET HR+5. Neuro Oncol. 2021;23(7):1163-72. doi: 10.1093/neuonc/noaa301
  20. Leary SES, Packer RJ, Li Y, et al. Efficacy of carboplatin and isotretinoin in children with high – risk medulloblastoma: A randomized clinical trial from the Children’s Oncology Group. JAMA Oncol. 2021;7(9):1313-21. doi: 10.1001/jamaoncol.2021.2224
  21. Rubin BY, Anderson SL. IKBKAP/ELP1 gene mutations: Mechanisms of familial dysautonomia and gene-targeting therapies. Appl Clin Genet. 2017;10:95-103. doi: 10.2147/TACG.S129638
  22. Waszak SM, Robinson GW, Gudenas BL, et al. Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature. 2020;580(7803):396-401. doi: 10.1038/s41586-020-2164-5
  23. Tauziède-Espariat A, Guerrini-Rousseau L, Perrier A, et al. Immunohistochemistry as a tool to identify ELP1 associated medulloblastoma. Acta Neuropathol. 2022;143(4):523-5. doi: 10.1007/s00401-022-02409-4
  24. Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog–subgroup medulloblastoma: Results from phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591
  25. Northcott PA, Robinson GW, Kratz CP, et al. Medulloblastoma. Nat Rev Dis Primers. 2019;5(1):11. doi: 10.1038/s41572-019-0063-6.

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies